High versus low radioiodine activity in patients with differentiated thyroid cancer: A meta-analysis

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970–1996: Time trends and age-period-cohort effects. Br J Cancer 2001;85:1335–9.
   PubMed Web of Science ®Google Scholar
• Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 2009;115:3801–7.
   PubMed Web of Science ®Google Scholar
• Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al. International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control 2009;20: 525–31.
   PubMed Web of Science ®Google Scholar
• How J, Tabah R. Explaining the increasing incidence of differentiated thyroid cancer. CMAJ 2007;177:1383–4.
   PubMed Web of Science ®Google Scholar
• Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668–76.
   PubMed Web of Science ®Google Scholar
• Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008;37:457–80.
   PubMed Web of Science ®Google Scholar
• Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787–803.
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, et al; National Comprehensive Cancer Network. Thyroid carcinoma. J Natl Compr Canc Netw 2010;8:1228–74.
   PubMed Web of Science ®Google Scholar
• Pacini F, Castagna MG, Brilli L, Pentheroudakis G; ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v214–9.
   Web of Science ®Google Scholar
• Reiners C, Farahati J. I131 therapy of thyroid cancer patient. Q J Nucl Med 1999;43:324–35.
   PubMedGoogle Scholar
• Creutzig H. High or low dose radioiodine ablation of thyroid remnants?Eur J Nucl Med 1987;12:500–2.
   PubMedGoogle Scholar
• Johansen K, Woodhouse NJY, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in post-operative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991;32:252–4.
   PubMed Web of Science ®Google Scholar
• Bal CS, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996;77:2574–80.
   PubMed Web of Science ®Google Scholar
• Gawkowska-Suwinska M, Turska M, Roskosz J, Puch Z, Jurecka-Tuleja B, Handkiewicz-Junak D, et al. Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer. Wiad Lek 2001;54(Suppl 1):278–88.
   PubMedGoogle Scholar
• Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: A randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004;89:1666–73.
   PubMed Web of Science ®Google Scholar
• Mäenpää HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: A randomized study. PLoS One 2008;3:e1885.
   PubMed Web of Science ®Google Scholar
• Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 2007;92:28–38.
   PubMed Web of Science ®Google Scholar
• Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, Saghari M, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: A large randomized clinical trial. Nucl Med Commun 2012;33:275–82.
   PubMed Web of Science ®Google Scholar
• Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012;366:1674–85.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al; Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation Equivalence Trial. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012;366:1663–73.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• , American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerCooper DS, Doherty GM, Haugen BR, Kloos RT, Le SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167–214.
   PubMed Web of Science ®Google Scholar
• Iyer NG, Morris LGT, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011;117:4439–46.
   PubMed Web of Science ®Google Scholar
• Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: A systematic review and meta-analysis. Thyroid 2009;19:451–7.
   PubMed Web of Science ®Google Scholar
• Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffé S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 2012;97:1526–35.
   PubMed Web of Science ®Google Scholar
• Kim EY, Kim TY, Kim WG, Yim JH, Han JM, Ryu JS, et al. Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma. Nucl Med Commun 2011;32:954–9.
   PubMed Web of Science ®Google Scholar
• Mallick U, Harmer C, Hackshaw A, Moss L. Iodine or Not (IoN) for low-risk differentiated thyroid cancer; the next UK National Cancer Research Network randomized trial following HiLo. Clin Oncol (R Coll Radiol) 2012;24:159–61.
   PubMed Web of Science ®Google Scholar
• Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878–84.
   PubMed Web of Science ®Google Scholar
• Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 2010;20:173–9.
   PubMed Web of Science ®Google Scholar
• Alexander EK, Larsen PR. Radioiodine for thyroid cancer – is less more?N Engl J Med 2012;366:1732–3.
   PubMed Web of Science ®Google Scholar
• Jones AP, Riley RD, Williamson PR, Whitehead A. Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clin Trials 2009;6:16–27.
   PubMed Web of Science ®Google Scholar